Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001549595-24-000049
Filing Date
2024-04-10
Accepted
2024-04-10 07:06:08
Documents
69
Period of Report
2024-02-29

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-20240229.htm   iXBRL 10-Q 1294641
2 EX-10.1 nrix-20240229xxex101sanofi.htm EX-10.1 31446
3 EX-10.2 nrix-20240229xxex102leasee.htm EX-10.2 27682
4 EX-31.1 nrix-20240229x10qxex311.htm EX-31.1 10853
5 EX-31.2 nrix-20240229x10qxex312.htm EX-31.2 10843
6 EX-32.1 nrix-20240229x10qxex321.htm EX-32.1 8428
  Complete submission text file 0001549595-24-000049.txt   5706436

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20240229.xsd EX-101.SCH 38015
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nrix-20240229_cal.xml EX-101.CAL 50515
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nrix-20240229_def.xml EX-101.DEF 176020
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20240229_lab.xml EX-101.LAB 527817
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20240229_pre.xml EX-101.PRE 356006
73 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20240229_htm.xml XML 560762
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 24834233
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)